We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Proteome Systems Sells Rights to Technology Products to Shimadzu

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteome Systems Sells Rights to Technology Products to Shimadzu"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Proteome Systems Ltd.has announced the sale of the rights to its award winning technologies, the Chemical Inkjet Printer (ChIP) instrument and Xcise, to Shimadzu Corporation.

Under the deal with Shimadzu, Proteome Systems will receive cash and the provision of Shimadzu’s latest mass spectrometer and protein separation technology.

This will position the Sydney-based company as a reference site for Shimadzu’s mass spectrometry technology and Shimadzu will have the benefit of Proteome Systems’s expertise in biomarker discovery methods for the development of new applications for its technology.

Proteome Systems’ CEO, Stephen Porges, said the move was integral to the overall corporate strategy of exiting its technology manufacturing operations to focus its resources on the significant successes of the core discovery and diagnostics business.

“This deal not only delivers on our previously stated strategy of reducing costs in our technology business, but also provides Proteome Systems with an ongoing strategic relationship with a global leader in the design and manufacture of analytical instruments, giving Proteome Systems direct access to the latest technology,” said Porges.

“Proteome Systems will become a reference site for Shimadzu, working on new mass spectrometry applications for discovery and validation of diagnostic markers and hosting visiting scientists from around the world.”

Diagnostics in development include Proteome Systems’s lead programme for a point of care test for active tuberculosis and a semen-based prostate cancer test.